Market Currents
InterMune (ITMN) +89% premarket after EU's CHMP recommends its lung disease treatment Esbriet...
-
Friday, December 17, 2010, 7:35 AM ETInterMune (ITMN) +89% premarket after EU's CHMP recommends its lung disease treatment Esbriet even earlier than expected. FDA rejected the drug in May, sending shares off a cliff. Esbriet would be the first effective treatment for the fatal disease idiopathic pulmonary fibrosis.
Other date
Latest Articles
